Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P67870
UPID:
CSK2B_HUMAN
Alternative names:
Phosvitin; Protein G5a
Alternative UPACC:
P67870; B0UXA9; P07312; P13862; Q4VX47
Background:
Casein kinase II subunit beta, also known as Phosvitin and Protein G5a, plays a crucial role in cellular processes. It acts as a regulatory subunit in the casein kinase II complex, influencing the kinase's basal catalytic activity. This protein is involved in phosphorylating substrates and participates in Wnt signaling, highlighting its importance in cell signaling pathways.
Therapeutic significance:
The protein is linked to Poirier-Bienvenu neurodevelopmental syndrome, a disorder marked by seizures, developmental delay, and impaired intellectual development. Understanding the role of Casein kinase II subunit beta could open doors to potential therapeutic strategies for this syndrome.